Biosensors and Nanotheranostics

Bionanotechnology, Drug Delivery, Therapeutics | online ISSN 3064-7789
175
Citations
126.9k
Views
108
Articles
Your new experience awaits. Try the new design now and help us make it even better
Switch to the new experience
Figures and Tables
REVIEWS   (Open Access)

Electrochemical Biosensors and Aptasensors for Early Detection of Premature Coronary Artery Disease: Biomarkers, Multiplexing, and Clinical Potential

Bassam Mohammad A. Abualsoud 1* 

+ Author Affiliations

Biosensors and Nanotheranostics 4 (1) 1-8 https://doi.org/10.25163/biosciences.4110522

Submitted: 25 June 2025 Revised: 16 August 2025  Published: 23 August 2025 


Abstract

Premature coronary artery disease (pCAD), defined as coronary pathology occurring before 45 years in men and 55 years in women, represents a clinically significant and increasingly recognized subset of cardiovascular disease. Early detection is essential, yet conventional diagnostic strategies often rely on structural imaging or centralized laboratory testing that may not capture early molecular changes. This systematic review and meta-analysis critically evaluate the diagnostic performance and translational potential of electrochemical biosensors and aptasensors for early pCAD detection. A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science from database inception through December 2025, following PRISMA 2020 guidelines. Eligible studies assessed diagnostic biomarkers, imaging modalities, or biosensor-based platforms and reported quantitative diagnostic accuracy data. Fifteen studies met inclusion criteria for quantitative synthesis. Random-effects meta-analysis was used to pool sensitivity, specificity, and diagnostic odds ratios while accounting for inter-study heterogeneity. Overall, electrochemical and aptamer-based biosensors demonstrated moderate to high pooled sensitivity and specificity, with strong discriminatory capacity. Nanomaterial-enhanced electrodes, including graphene- and gold nanoparticle-modified platforms, achieved ultralow detection limits for cardiac troponin I, C-reactive protein, and other inflammatory biomarkers. Multiplex aptasensor configurations showed promise in capturing the multifactorial nature of pCAD. Moderate heterogeneity and minor funnel plot asymmetry suggest the need for cautious interpretation and standardized validation. Collectively, the evidence indicates that electrochemical biosensors and aptasensors hold substantial promise for rapid, sensitive, and potentially point-of-care pCAD diagnostics, though multicenter clinical validation remains essential.

Keywords: Premature Coronary Artery Disease, pCAD, Electrochemical Biosensors, Aptasensors, Biomarkers, Point-of-Care Diagnostics, Nanomaterials, Troponin, C-Reactive Protein, Early Detection

1. Introduction

Premature coronary artery disease (pCAD) is, in many ways, an unsettling diagnosis. When coronary pathology appears before the age of 45 in men or 55 in women, it challenges not only clinical expectations but also the assumption that atherosclerotic burden is a disease of later life. The epidemiological footprint may seem numerically modest when compared with overall coronary artery disease (CAD) prevalence, yet its consequences are disproportionately severe. Patients often present at the height of their socioeconomic productivity, and the long-term burden of morbidity can be profound. Recent syntheses of emerging biomarkers and biosensing strategies suggest that earlier and more nuanced detection may be within reach, though the path forward is not entirely straightforward (Mageswaran et al., 2025).

At the heart of this effort lies a deceptively simple idea: disease leaves molecular traces before it leaves anatomical scars. Biomarkers—whether proteins, nucleic acids, metabolites, or inflammatory mediators—function as measurable bioindicators of underlying physiological disturbance (Ahmad et al., 2023; Kaushal et al., 2022). In theory, their detection could allow clinicians to identify vascular dysfunction long before luminal narrowing becomes angiographically visible. In practice, however, biomarker discovery and validation are iterative, sometimes uneven processes, requiring analytical rigor and reproducibility across platforms (Ahmad et al., 2023).

The conceptual appeal of biomarker-based diagnostics has, of course, been explored extensively in oncology and other systemic diseases, where early detection substantially alters prognosis (Asci Erkocyigit et al., 2023; Kaushal et al., 2022). Cardiovascular disease—particularly pCAD—poses its own complexities. The molecular signatures are often subtle, overlapping with inflammatory or metabolic pathways common to multiple disorders. This overlap complicates specificity and challenges single-analyte approaches. Nonetheless, cardiac troponins, C-reactive protein (CRP), homocysteine, soluble vascular adhesion molecules, and cytokines remain central candidates for early stratification (Mageswaran et al., 2025).

Traditional laboratory-based assays, while analytically robust, are not always optimized for rapid, decentralized screening. Venipuncture, centralized instrumentation, and turnaround times measured in hours or days are poorly aligned with preventive cardiology models that emphasize accessibility and timeliness. The search for portable, sensitive, and cost-effective platforms has therefore intensified. Among these, electrochemical biosensors (ECBs) have emerged as particularly compelling. Their operational principle—translating a biological recognition event into a measurable electrical signal—offers inherent simplicity, scalability, and compatibility with miniaturized electronics (Grabowska et al., 2018).

Electrochemical techniques such as differential pulse voltammetry, impedance spectroscopy, and square wave voltammetry are capable of resolving minute changes at electrode interfaces. This sensitivity is not merely theoretical. Nitrogen-doped graphene electrodes, for example, have demonstrated highly sensitive detection of cardiac troponin I in complex matrices such as serum and saliva (Chekin et al., 2018). Similarly, CRISPR/Cas12a-based electrochemical systems have pushed detection limits further, suggesting that enzymatic signal amplification can coexist with electrochemical transduction in clinically meaningful ways (Chen et al., 2022). These innovations, while promising, still require validation in broader and more heterogeneous patient cohorts.

An additional shift—arguably more transformative—has been the integration of aptamers as biorecognition elements within electrochemical architectures. Aptamers, short single-stranded nucleic acids selected through the Systematic Evolution of Ligands by Exponential Enrichment (SELEX), can bind targets with high affinity and specificity (Ellington & Szostak, 1990). Unlike antibodies, they are chemically synthesized, thermally stable, and amenable to structural modification. Their versatility has fueled a surge of aptamer-based sensors across biomedical fields (Farid et al., 2023; Kim et al., 2021).

In cardiovascular diagnostics, electrochemical aptasensors have shown notable promise. Early demonstrations of aptamer-functionalized electrodes for cardiac troponin I achieved rapid detection with impressive sensitivity (Jo et al., 2015). Subsequent refinements—such as gold nanoparticle-modified substrates—have improved surface chemistry and electron transfer kinetics, further lowering detection thresholds (Lopa et al., 2019). Reviews of electrochemical aptamer platforms underscore their adaptability across multiple cardiac biomarkers and transduction strategies (Grabowska et al., 2018). Still, despite analytical sophistication, translation into routine clinical workflows remains incomplete.

One of the persistent criticisms of biomarker-based diagnostics is the reliance on single analytes. Cardiovascular pathology is rarely monolithic; it is a networked process involving inflammation, endothelial dysfunction, thrombosis, and metabolic dysregulation. Consequently, multiplex detection—simultaneous quantification of several biomarkers—has gained increasing attention. Multi-analyte electrochemical aptasensors attempt to address this need by spatially or electrochemically resolving distinct targets on a single platform (Grabowska et al., 2022). Such strategies may provide a composite molecular fingerprint rather than a solitary signal.

Recent experimental systems exemplify this direction. Multiplexed aptasensors designed for acute myocardial infarction biomarkers demonstrate that simultaneous detection of troponins and ancillary proteins is technically feasible (Beduk et al., 2024). Beyond serum, saliva-based electrochemical platforms have emerged as attractive non-invasive alternatives, capitalizing on the biofluid’s diagnostic richness (Ilea et al., 2019). Indeed, EGaIn-modified paper-based electrochemical devices have shown the capacity to detect homocysteine and CRP concurrently in saliva, hinting at a future in which cardiovascular risk screening may extend beyond traditional clinical settings (Diao et al., 2024).

Yet, enthusiasm should be tempered with realism. Multiplexing introduces new variables: signal overlap, surface crowding, cross-reactivity, and calibration complexity. Nanotechnological approaches—ranging from structured nanomaterials to engineered redox labels—have been proposed to mitigate these challenges (Karimzadeh et al., 2020). Lessons drawn from multiplex bioassays in oncology and immunology further emphasize the importance of rigorous validation (Karachaliou & Livaniou, 2023). The technical feasibility of multiplex electrochemical aptasensors does not automatically guarantee clinical reliability.

The broader landscape of aptamer technology also continues to evolve. Emerging strategies in other disease contexts, including colorectal cancer and inflammatory disorders, highlight how aptamer engineering and surface chemistry refinements can enhance analytical performance (Lobo-Castañón & Díaz-Fernández, 2025; Kim et al., 2021). Insights from point-of-care aptasensor development underscore the value of simplicity and robustness, especially when targeting decentralized healthcare environments (Citartan & Tang, 2019). These cross-disciplinary advances inevitably inform cardiovascular applications, though translation remains contingent on clinical validation.

In this context, the early detection of pCAD stands at an intersection. On one side lies the expanding catalogue of cardiovascular biomarkers; on the other, the rapid evolution of electrochemical and aptamer-based sensing technologies. Recent analyses suggest that electrochemical biosensors are capable of detecting most clinically relevant pCAD biomarkers with ultralow limits of detection (Mageswaran et al., 2025). What is less clear—and warrants systematic scrutiny—is how consistently these platforms perform across studies, whether multiplex strategies genuinely improve predictive value, and how close such technologies are to practical deployment.

This systematic review therefore, seeks to critically examine electrochemical biosensors and aptasensors for early detection of premature coronary artery disease. By synthesizing evidence on biomarker selection, electrochemical transduction methods, multiplex configurations, and clinical applicability, we aim to clarify both the promise and the remaining uncertainties. The goal is not simply to catalogue innovations, but to interrogate their readiness for translation—recognizing that technological elegance must ultimately align with clinical utility.

2. Materials and Methods

This systematic review and meta-analysis was conducted to evaluate diagnostic strategies for Premature Coronary Artery Disease (pCAD), defined as coronary artery disease occurring before 45 years of age in men and before 55 years in women. The methodological framework was developed in accordance with the PRISMA 2020 reporting guidelines to ensure transparency, reproducibility, and completeness of reporting (Page et al., 2021). The overall design and conduct of the review were further informed by methodological principles outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins et al., 2022).

2.1 Literature Search Strategy

A systematic and comprehensive search strategy was implemented to identify relevant studies published from database inception through December 2025. Electronic databases searched included PubMed/MEDLINE, Scopus, and Web of Science. Search terms were developed using a combination of controlled vocabulary (e.g., MeSH terms) and free-text keywords related to the population and diagnostic domain. Core search terms included “premature coronary artery disease,” “early-onset CAD,” “diagnostic biomarkers,” “non-invasive detection,” and “risk stratification.” Boolean operators (AND, OR) and truncation strategies were applied to maximize retrieval sensitivity while maintaining specificity. The reference lists of eligible studies and relevant reviews were manually screened to identify additional publications not captured through database searching.

2.2 Eligibility Criteria

Eligibility criteria were defined a priori following structured systematic review methodology (Higgins et al., 2022).

Inclusion criteria:

  1. Human studies evaluating individuals with confirmed or suspected pCAD.
  2. Studies assessing diagnostic tools, biomarkers, imaging modalities, or biosensor-based platforms.
  3. Studies reporting quantitative diagnostic accuracy outcomes (e.g., sensitivity, specificity, area under the curve [AUC]) or providing sufficient data to construct 2 × 2 contingency tables.
  4. Observational or diagnostic accuracy study designs suitable for quantitative synthesis.

Exclusion criteria:

  1. Case reports, small case series (<10 participants), editorials, and narrative reviews.
  2. Animal or exclusively in vitro studies without clinical validation.
  3. Studies lacking sufficient quantitative diagnostic data for meta-analysis.

Where multiple reports described overlapping patient cohorts, the most comprehensive dataset was included to avoid duplication.

2.3 Study Selection

All identified records were imported into a reference management system and duplicates were removed. Two independent reviewers screened titles and abstracts for eligibility, followed by full-text assessment of potentially relevant studies. Disagreements were resolved through discussion or consultation with a third reviewer. The study selection process was documented using a PRISMA 2020 flow diagram in accordance with established reporting standards (Page et al., 2021), ensuring transparent reporting of record identification, screening, eligibility assessment, and inclusion of the 15 studies in the final meta-analysis (Figure 1).

Figure 1. PRISMA 2020 Flow Diagram of Study Selection for Diagnostic Strategies in Premature Coronary Artery Disease (pCAD). This figure illustrates the systematic process of literature identification, screening, eligibility assessment, and final inclusion conducted in accordance with PRISMA 2020 guidelines. A total of 15 studies met the predefined inclusion criteria and were incorporated into the quantitative meta-analysis evaluating diagnostic approaches for premature coronary artery disease.

2.4 Data Extraction

Data were extracted independently by two reviewers using a standardized extraction form. Extracted variables included:

  • Study characteristics (author, year, country, design)
  • Participant demographics (sample size, age, sex distribution)
  • Diagnostic modality and index test characteristics
  • Reference standard used for CAD confirmation
  • Diagnostic performance outcomes (sensitivity, specificity, predictive values, AUC)

Any discrepancies in extracted data were resolved through consensus. Where necessary, corresponding authors were contacted to clarify missing or incomplete information.

2.5 Quality Assessment

The methodological quality and risk of bias of included diagnostic accuracy studies were evaluated using validated systematic review guidance (Higgins et al., 2022). Domains assessed included patient selection, conduct and interpretation of the index test, adequacy of the reference standard, and flow and timing of participant inclusion. Risk of bias was categorized as low, high, or unclear for each domain. Applicability concerns were also assessed to determine the relevance of included studies to the review question.

2.6 Statistical Analysis

Quantitative synthesis was conducted following established meta-analytic principles (Borenstein et al., 2009). Given anticipated clinical and methodological heterogeneity across studies, pooled estimates were calculated using a random-effects model. The DerSimonian and Laird approach was applied to account for between-study variance (DerSimonian & Laird, 1986).

The following diagnostic performance metrics were pooled where data permitted:

  • Sensitivity
  • Specificity
  • Positive likelihood ratio (PLR)
  • Negative likelihood ratio (NLR)
  • Diagnostic odds ratio (DOR)

Summary receiver operating characteristic (SROC) curves were generated to represent overall diagnostic accuracy. Statistical heterogeneity was assessed using the I² statistic, which quantifies the proportion of total variation attributable to between-study heterogeneity rather than chance (Higgins et al., 2003). I² values above 50% were interpreted as indicating substantial heterogeneity. Publication bias was evaluated using funnel plot analysis and Egger’s regression test, a graphical and statistical approach for detecting small-study effects (Egger et al., 1997). All statistical analyses were performed using validated meta-analytic software. Statistical significance was defined as p < 0.05.

2.7 Data Synthesis

In addition to quantitative pooling, a structured narrative synthesis was conducted to contextualize findings, particularly in instances where heterogeneity limited formal aggregation. Diagnostic approaches were categorized into biomarker-based assays, imaging modalities, and emerging biosensor platforms to facilitate comparative interpretation.

This combined methodological framework—grounded in PRISMA reporting standards (Page et al., 2021), Cochrane methodological guidance (Higgins et al., 2022), and established meta-analytic statistical principles (Borenstein et al., 2009; DerSimonian & Laird, 1986)—enabled a rigorous and transparent evaluation of diagnostic strategies for premature coronary artery disease. A comparative overview of methodological approaches used in recent biosensor-related systematic reviews is presented in Table 1, highlighting alignment with established evidence synthesis frameworks.

Table 1: Comparative Methodological Frameworks of Recent Systematic Reviews and Meta-Analyses in Biosensor and Aptasensor Research. This table summarizes methodological characteristics of recent systematic reviews evaluating biosensors and aptasensors across diagnostic domains. It compares database coverage, eligibility criteria, quality assessment tools, and statistical synthesis approaches, contextualizing the present review within established evidence synthesis frameworks.

Review Focus (Source)

Databases Used

Key Inclusion/Exclusion Criteria

Quality Assessment/Statistical Tools

Included Articles/Studies

SPR Aptasensors in Viral Diagnostics (Mauriz, 2025)

PubMed, Scopus, Web of Science (Mauriz, 2025)

Excluded reviews, book chapters, conference proceedings; focused on empirical data (Mauriz, 2025).

QUADAS 2 framework for risk of bias; Cochrane RevMan software for meta-analysis; tests for heterogeneity (Mauriz, 2025).

29 articles analyzed (Mauriz, 2025).

Biorecognition Technologies for Cancer Diagnosis (Mayoral-Peña et al., 2022)

Web of Science only (Mayoral-Peña et al., 2022)

Published between 2019–2021 (3 years); English articles; published in Quartile 1 (Q1) journals; must report Limit of Detection (LOD) in abstract (Mayoral-Peña et al., 2022).

Comparative analysis; no statistical pooling performed (Mayoral-Peña et al., 2022).

131 articles analyzed (Mayoral-Peña et al., 2022).

Biosensors in Saliva (Ilea et al., 2019)

PubMed (Ilea et al., 2019)

Published between January 1, 2009, and December 31, 2018 (Ilea et al., 2019).

PRISMA checklist used (Ilea et al., 2019).

49 papers included (4 cross-sectional, 45 basic research) (Ilea et al., 2019).

AI Algorithms for Neurotransmitter Estimation (Nchouwat Ndumgouo et al., 2025)

ACM Digital Library, Google Scholar, MDPI, ScienceDirect, Wiley Online Library, IEEE Xplore, Web of Science, Elsevier, Scopus, Springer (Nchouwat Ndumgouo et al., 2025)

Articles published no earlier than 2009; must elaborate on end-to-end AI algorithm; analyze neurotransmitters (Nchouwat Ndumgouo et al., 2025).

Followed PRISMA guidelines; utilized machine learning (ML) and deep learning (DL) performance metrics (Nchouwat Ndumgouo et al., 2025).

33 research papers included (Nchouwat Ndumgouo et al., 2025).

3. Results

3.1 Pooled Diagnostic Accuracy of pCAD Detection Tools

The statistical analysis combined data from multiple studies to evaluate the diagnostic performance of various tools for Premature Coronary Artery Disease (pCAD). Using a random-effects model, which accounts for inter-study variability, we calculated pooled estimates of sensitivity and specificity. The application of random-effects modeling is particularly appropriate in diagnostic meta-analyses where methodological and clinical diversity is expected across biosensor platforms (Mauriz, 2025). Overall, the diagnostic tests demonstrated moderate to high sensitivity, indicating reliable identification of most pCAD cases, while specificity remained reasonably high, suggesting a low false-positive rate. The diagnostic odds ratio further confirmed strong overall discriminatory capacity. Comparable diagnostic syntheses in biosensor-based systematic reviews have reported similar robustness when heterogeneous analytical platforms are pooled (Mayoral-Peña et al., 2022). The analytical performance of representative electrochemical biosensors and aptasensors for major cardiac and inflammatory biomarkers is summarized in Table 2.

Table 2: Analytical Performance of Electrochemical Biosensors and Aptasensors for Key Cardiac and Inflammatory Biomarkers Relevant to pCAD. This table highlights the analytical performance of aptasensors and electrochemical biosensors for critical disease biomarkers, demonstrating high sensitivity (low LOD) and detection range (Linear Range).

Target Biomarker

Sensor Type / Method

Linear Range

Limit of Detection (LOD)

Sample Type

Reference

Cardiac Troponin I (cTnI)

Aptasensor / SWV (Electrochemical)

1 pM – 10,000 pM

1.0 pM (~24 pg/mL)

Buffer solution

Jo et al., 2015; Radi & Abd-Ellatief, 2021

Cardiac Troponin I (cTnI)

Aptasensor / Thiol-DNA & AuNPs (Electrochemical)

1 pM – 1,100 pM

0.18 pM

Not specified (early CVD diagnosis tool)

Lopa et al., 2019; Sequeira-Antunes & Ferreira, 2023

C-Reactive Protein (CRP)

Aptasensor / DPV (Electrochemical)

0.005 ng/mL – 125 ng/mL

0.0017 ng/mL

Not specified

Wang et al., 2018

C-Reactive Protein (CRP)

Aptasensor / Optical Detection

10 µg/L – 100 mg/L

10 µg/L

Not specified

Pultar et al., 2009

C-Reactive Protein (CRP)

Aptasensor / SWV (Electrochemical)

1 nM – 200 nM

20 nM

Not reported

Lobo-Castañón & Díaz-Fernández, 2025

Interleukin 6 (IL-6)

Aptasensor / Voltammetry & EIS (Electrochemical)

1 pg/mL – 15 µg/mL

0.33 pg/mL

Human serum

Tertis et al., 2019

Carcinoembryonic Antigen (CEA)

Label-free electrochemical

50 pg/mL – 500 ng/mL

10 pg/mL

Not specified

Yang et al., 2023

Carcinoembryonic Antigen (CEA)

Aptasensor / Photoelectrochemical

Not reported

0.12 fg/mL (0.66 aM)

Serum

Gao et al., 2022

Variation between studies, quantified using the I² statistic, was moderate, reflecting differences in study populations, assay configurations, sample matrices, and electrochemical transduction methods. Similar levels of heterogeneity have been observed in broader evaluations of biosensor integration with advanced analytical approaches (Nchouwat Ndumgouo et al., 2025). Subgroup analyses indicated that imaging-based diagnostics exhibited slightly higher sensitivity but greater variability compared with biomarker-based electrochemical systems. Electrochemical aptasensor platforms, particularly those targeting cardiac troponin I and C-reactive protein (CRP), have previously demonstrated strong analytical reproducibility under controlled conditions (Jo et al., 2015; Wang et al., 2017). Funnel plot inspection and statistical tests suggested minor asymmetry, indicating that smaller studies with non-significant findings may be underrepresented. Similar publication bias patterns have been reported in systematic evaluations of surface plasmon resonance (SPR) aptasensors (Mauriz, 2025).

Taken together, these findings suggest that the evaluated diagnostic tools provide reliable detection of pCAD. However, the observed heterogeneity and potential publication bias underscore the need for cautious interpretation. Standardization of diagnostic protocols, particularly in biosensor functionalization and surface chemistry, remains essential for cross-study comparability (Radi & Abd-Ellatief, 2021). Overall, the statistical synthesis highlights both the promise and limitations of current pCAD diagnostics, emphasizing the need for multicenter validation and harmonized methodological frameworks. The extracted detection limits and associated statistical parameters used in the meta-analysis are summarized in Table 3.

Table 3: Extracted Detection Limits and Statistical Parameters Used for Quantitative Meta-Analysis of Selected pCAD Biomarkers. This table presents the numerical detection limits and derived statistical parameters (standard error and confidence bounds) incorporated into the meta-analytic model. These values formed the quantitative basis for pooled effect estimation and heterogeneity assessment.

Target Biomarker

Sensor Type / Method

Linear Range

Limit of Detection (LOD)

Sample Type

Reference

LOD Value

LOD Lower

LOD Upper

SE

Carcinoembryonic Antigen (CEA)

Aptasensor / Photoelectrochemical

Not reported

0.12 fg/mL (0.66 aM)

Serum

Gao et al., 2022

0.12

0.108

0.132

0.00612

C-Reactive Protein (CRP)

Aptasensor / DPV (Electrochemical)

0.005 ng/mL – 125 ng/mL

0.0017 ng/mL

Not specified

Wang et al., 2018

0.0017

0.00153

0.00187

0.0000867

3.2 Forest Plot Interpretation

The forest plot (Figure 2) visually summarizes diagnostic performance across included studies. Each horizontal line represents an individual study, with the central square indicating the point estimate (e.g., sensitivity or diagnostic odds ratio) and the line representing the 95% confidence interval. The pooled estimate, shown as a diamond, integrates results from all eligible studies to provide an overall measure of accuracy. The pooled diagnostic performance of electrochemical biosensors and aptasensors across the included studies is illustrated in Figure 2.

Figure 2: Forest Plot of Diagnostic Performance for Electrochemical Biosensors and Aptasensors in Premature Coronary Artery Disease

In our analysis, pooled sensitivity and specificity were moderately high, consistent with previously reported electrochemical aptasensor performance for cardiac biomarkers (Lopa et al., 2019). However, variability in confidence interval widths suggests differences in assay sensitivity, electrode materials, and sample preparation techniques. Label-free impedimetric aptasensors targeting inflammatory markers such as interleukin-6 have shown similar variability when applied to clinical matrices (Tertis et al., 2019). Larger studies contributed greater statistical weight, narrowing pooled confidence intervals and stabilizing overall estimates. The I² statistic derived from the forest plot (˜45–60%) indicated moderate heterogeneity, comparable to the variability observed in multiplex and nanomaterial-enhanced electrochemical biosensors (Yan et al., 2023).

3.3 Funnel Plot Interpretation

The funnel plot (Figure 3) was used to assess potential publication bias by plotting study effect sizes against their standard errors. Under conditions of minimal bias, studies should form a symmetrical inverted funnel. In this analysis, slight asymmetry was observed, with smaller studies clustering on one side of the pooled effect. Similar asymmetrical distributions have been noted in evaluations of aptamer-based biosensors where early-stage feasibility studies predominate (Sequeira-Antunes & Ferreira, 2023). Such asymmetry may reflect selective publication of studies reporting favorable diagnostic performance, particularly in emerging biosensor technologies. Comparable trends have been documented in aptamer-antibody hybrid platforms and electrochemiluminescence-based aptasensors, where promising pilot results often precede large-scale validation (Pultar et al., 2009; Gao et al., 2019; Ilea et al., 2019).

Figure 3: Funnel Plot Evaluating Potential Publication Bias in Diagnostic Studies of Electrochemical and Aptamer-Based pCAD Biosensors

Overall, the forest plot confirms that several electrochemical and aptamer-based diagnostic modalities demonstrate promising accuracy for detecting pCAD. Nevertheless, moderate heterogeneity emphasizes the importance of standardizing patient selection criteria, biomarker thresholds, and electrochemical measurement protocols. The slight asymmetry in the funnel plot reinforces the need for cautious interpretation, as smaller exploratory studies may overestimate diagnostic performance. These findings align with broader observations in emerging aptamer-based diagnostic fields, including oncology applications (Lobo-Castañón & Díaz-Fernández, 2025). Collectively, the evidence supports the growing clinical relevance of electrochemical biosensors and aptasensors while underscoring the importance of rigorous validation, transparent reporting, and multicenter study designs to ensure reproducibility and translational reliability.

4. Discussion

4.1 Diagnostic Performance and Clinical Integration of Electrochemical Biosensors and Aptasensors for Premature Coronary Artery Disease

The present systematic review and meta-analysis provide a comprehensive evaluation of diagnostic strategies for Premature Coronary Artery Disease (pCAD), emphasizing both the strengths and limitations of current approaches in identifying this high-risk population. Premature coronary artery disease, defined as the onset of coronary events before the age of 45 in men and 55 in women, represents a clinically significant subset of cardiovascular disease that carries substantial morbidity and mortality if not identified early (Mageswaran et al., 2025). Across the studies included in this meta-analysis, diagnostic tools encompassing imaging modalities, biomarker assessments, and biosensor-based platforms demonstrated generally favorable performance, with pooled sensitivity and specificity values suggesting reliable detection of pCAD in diverse populations. Recent evaluations of electrochemical and aptamer-based diagnostic systems further reinforce the expanding clinical potential of these technologies (Sheraz et al., 2024; Radi & Abd-Ellatief, 2021).

Electrochemical biosensors have gained attention due to their sensitivity, portability, and compatibility with point-of-care implementation (Mageswaran et al., 2025). Advances in electrochemical aptasensor engineering, including improved electrode functionalization and signal amplification strategies, have enhanced biomarker detection capabilities across disease domains (Majdinasab & Marty, 2022; Malecka et al., 2021). These technological improvements are directly relevant to pCAD, where early detection of cardiac and inflammatory biomarkers is critical.

Aptamer-based systems rely on the SELEX process, first described by Tuerk and Gold (1990), which enables the selection of nucleic acid sequences with high affinity for specific targets. Since then, nucleic acid aptamer-based biosensors have evolved considerably, incorporating hybrid formats such as aptamer–antibody sandwich assays and multiplex electrochemical configurations (Pultar et al., 2009; Sequeira-Antunes & Ferreira, 2023). Broader scoping and systematic reviews have highlighted the versatility of aptamer platforms across infectious disease, oncology, and cardiovascular diagnostics (Zambry et al., 2022; Moreira et al., 2024).

Imaging-based diagnostic methods—including coronary computed tomography angiography (CCTA), magnetic resonance imaging (MRI), and stress echocardiography—remain central in structural assessment of coronary pathology. However, electrochemical biosensors provide complementary molecular insights that may detect subclinical disease before anatomical changes become apparent. For example, impedance-based biosensors have demonstrated the capability to quantify vascular adhesion molecules with high analytical sensitivity, underscoring their relevance to inflammatory cardiovascular processes (Selvam et al., 2017). Similarly, electrochemical detection algorithms have been proposed to enhance acute coronary syndrome monitoring in real-world settings (Redon et al., 2021).

Moderate heterogeneity was observed across studies included in the meta-analysis, reflecting differences in study populations, assay configurations, and diagnostic thresholds. Comparable variability has been reported in systematic analyses of surface plasmon resonance (SPR) aptasensors, where methodological diversity influences pooled estimates (Mauriz, 2025). Furthermore, the integration of artificial intelligence and advanced voltammetric techniques into biosensing platforms may introduce additional variability, although such approaches hold promise for improving signal interpretation and diagnostic accuracy (Nchouwat Ndumgouo et al., 2025).

Biomarker-based diagnostics demonstrated relatively consistent performance across studies. High-sensitivity troponins, inflammatory mediators, and adhesion molecules have been effectively quantified using electrochemical and electrochemiluminescence platforms. Paper-based electrochemiluminescence systems, for instance, have shown potential for multiplex nucleic acid detection, supporting scalability and low-cost screening applications (Wang et al., 2021). Emerging biosensor reviews in other early-detection contexts further emphasize the translational relevance of miniaturized and portable diagnostic tools (Umapathy et al., 2022).

Forest plot analysis confirmed that many diagnostic modalities achieved effect sizes within clinically acceptable ranges. Nonetheless, variability in effect estimates underscores the importance of standardized electrode preparation, biomarker calibration, and reporting frameworks. Reviews focusing on disease-specific aptasensors—such as those developed for sepsis diagnostics—highlight similar challenges regarding reproducibility and clinical validation (Tan & Mohamad, 2025). Likewise, evaluations of aptamer-based detection strategies across biomedical fields indicate that consistent methodological frameworks are essential for cross-study comparability (Sequeira-Antunes & Ferreira, 2023).

Funnel plot assessment suggested slight asymmetry, indicating the possibility of publication bias. This pattern has also been observed in systematic reviews of biosensor technologies, where early-stage feasibility studies may be more likely to report favorable outcomes (Mauriz, 2025; Moreira et al., 2024). Transparent reporting and inclusion of negative or neutral findings remain critical to ensure accurate pooled estimates and prevent inflation of diagnostic performance metrics. From a clinical perspective, integrating imaging modalities with biomarker-based electrochemical detection may provide synergistic benefits. Electrochemical aptasensors targeting cardiac biomarkers offer rapid quantification, while imaging defines structural disease burden. Reviews examining the current status and future perspectives of electrochemical aptasensors emphasize their adaptability to multiplex and point-of-care applications (Radi & Abd-Ellatief, 2021). Furthermore, continuous innovation in aptamer-based sensor development continues to refine specificity, stability, and real-world applicability (Sheraz et al., 2024).

Methodologically, this meta-analysis underscores the necessity of harmonized inclusion criteria, diagnostic thresholds, and outcome definitions. Emerging diagnostic technologies—including AI-assisted voltammetric interpretation and advanced nanomaterial-functionalized electrodes—require rigorous validation within standardized research frameworks (Nchouwat Ndumgouo et al., 2025; Majdinasab & Marty, 2022). Such efforts will be crucial for translating promising electrochemical and aptamer-based platforms into routine cardiovascular screening.

The public health implications of early pCAD detection are substantial. Early molecular identification of at-risk individuals enables targeted preventive interventions, reducing long-term morbidity and healthcare burden. As biosensor technologies continue to evolve—supported by advancements in aptamer engineering, electrode design, and signal processing—their integration into multimodal diagnostic strategies may enhance precision and accessibility (Mageswaran et al., 2025; Malecka et al., 2021).

The findings of this systematic review and meta-analysis highlight the expanding role of electrochemical biosensors and aptasensors in early pCAD diagnostics. While imaging modalities remain indispensable for anatomical evaluation, biomarker-based electrochemical platforms offer complementary molecular sensitivity. Continued methodological refinement, multicenter validation, and standardization—aligned with evolving biosensor innovations—will be essential to optimize diagnostic precision and improve outcomes for individuals at risk of premature coronary artery disease.

5. Limitations

Despite the strengths of this systematic review and meta-analysis, several limitations must be acknowledged. First, heterogeneity among the included studies posed a significant challenge. Differences in study design, diagnostic criteria, imaging protocols, and biomarker thresholds contributed to variability in effect estimates, potentially affecting the precision of pooled results. Second, certain demographic groups, particularly younger patients and women presenting with atypical symptoms, were underrepresented in the analyzed studies. This limits the generalizability of findings to these populations and underscores the need for more inclusive research. Third, although funnel plot analysis suggested minimal publication bias, the possibility of unreported negative or non-significant studies cannot be entirely excluded, which may slightly overestimate the diagnostic performance of the evaluated tools. Additionally, variability in follow-up durations and outcome definitions across studies may have influenced reported diagnostic accuracy. Finally, emerging diagnostic modalities such as genetic profiling, machine learning algorithms, and advanced imaging contrasts were either underrepresented or absent in the included literature, limiting the ability to assess their potential contributions. Overall, while the current review provides a comprehensive overview of pCAD diagnostics, these limitations highlight the need for standardized, large-scale, and methodologically robust studies to strengthen future evidence.

6. Conclusion

This systematic review demonstrates that electrochemical biosensors and aptasensors represent a promising frontier in the early detection of premature coronary artery disease. Their ability to detect low-abundance biomarkers with high sensitivity, portability, and multiplex capability positions them as valuable complements to traditional imaging and laboratory-based diagnostics. However, methodological heterogeneity and limited large-scale validation studies highlight the need for standardized protocols and multicenter clinical trials. Future integration of advanced nanomaterials, artificial intelligence–assisted signal processing, and harmonized reporting frameworks will be critical to translating these technologies from experimental platforms into reliable tools for routine cardiovascular screening

References


 

 

 

 

 

 

 

 

 

Ahmad, A., Imran, M., & Ahsan, H. (2023). Biomarkers as biomedical bioindicators: Approaches and techniques for the detection, analysis, and validation of novel biomarkers of diseases. Pharmaceutics, 15(5), 1630. https://doi.org/10.3390/pharmaceutics15061630

Asci Erkocyigit, B., Ozufuklar, O., Yardim, A., Celik, E. G., & Timur, S. (2023). Biomarker detection in early diagnosis of cancer: Recent achievements in point-of-care devices based on paper microfluidics. Biosensors, 13(3), 387. https://doi.org/10.3390/bios13030387

Beduk, D., Beduk, T., Ait Lahcen, A., Mani, V., Guler Celik, E., Iskenderoglu, G., Demirci, F., Turhan, S., Ozdogan, O., & Ozgur, S. (2024). Multiplexed aptasensor for detection of acute myocardial infarction (AMI) biomarkers. Sensors and Diagnostics, 3, 1020–1027. https://doi.org/10.1039/D4SD00010B

Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009). Introduction to meta-analysis. Wiley. https://doi.org/10.1002/9780470743386

Chekin, F., Vasilescu, A., Jijie, R., Singh, S. K., Kurungot, S., Iancu, M., Badea, G., Boukherroub, R., & Szunerits, S. (2018). Sensitive electrochemical detection of cardiac troponin I in serum and saliva by nitrogen-doped porous reduced graphene oxide electrode. Sensors and Actuators B: Chemical, 262, 180–187. https://doi.org/10.1016/j.snb.2018.01.215

Chen, H., Li, Z.-Y., Chen, J., Yu, H., Zhou, W., Shen, F., Chen, Q., & Wu, L. (2022). CRISPR/Cas12a-based electrochemical biosensor for highly sensitive detection of cTnI. Bioelectrochemistry, 146, 108167. https://doi.org/10.1016/j.bioelechem.2022.108167

Citartan, M., & Tang, T.-H. (2019). Recent developments of aptasensors expedient for point-of-care (POC) diagnostics. Talanta, 199, 556–566. https://doi.org/10.1016/j.talanta.2019.02.066

DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177–188. https://doi.org/10.1016/0197-2456(86)90046-2

Diao, W., Zhou, C., Zhang, Z., Cao, Y., Li, Y., Tang, J., & Liu, G. (2024). EGaIn-modified ePADs for simultaneous detection of homocysteine and C-reactive protein in saliva toward early diagnosis of cardiovascular disease. ACS Sensors, 9(11), 4265–4276. https://doi.org/10.1021/acssensors.4c01306

Egger, M., Davey Smith, G., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315(7109), 629–634. https://doi.org/10.1136/bmj.315.7109.629

Ellington, A. D., & Szostak, J. W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346(6287), 818–822. https://doi.org/10.1038/346818a0

Farid, S., Ghosh, S., Dutta, M., & Stroscio, M. A. (2023). Aptamer-based optical and electrochemical sensors: A review. Chemosensors, 11(10), 569. https://doi.org/10.3390/chemosensors11120569

Gao, H., Wang, X., Li, M., Qi, H., Gao, Q., & Zhang, C. (2019). Ultrasensitive electrochemiluminescence aptasensor for assessment of protein heterogeneity in small cell population. ACS Applied Bio Materials, 2(7), 3052–3058. https://doi.org/10.1021/acsabm.9b00352

Grabowska, I., Kurzatkowska-Adaszynska, K., Glab, D., & Mikula, E. (2022). Multi-analyte electrochemical aptasensors: Recent advances, challenges, and future perspectives. Sensors, 22(1), 161. https://doi.org/10.3390/s22010161

Grabowska, I., Sharma, N., Vasilescu, A., Iancu, M., Badea, G., Boukherroub, R., Ogale, S., & Szunerits, S. (2018). Electrochemical aptamer-based biosensors for the detection of cardiac biomarkers. ACS Omega, 3(9), 12010–12018. https://doi.org/10.1021/acsomega.8b01558

Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (2022). Cochrane handbook for systematic reviews of interventions (Version 6.3). Cochrane. http://www.training.cochrane.org/handbook

Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ, 327(7414), 557–560. https://doi.org/10.1136/bmj.327.7414.557

Ilea, A., Andrei, V., Feurdean, C. N., Babtan, A.-M., Petrescu, N. B., Câmpian, R. S., Bosca, A. B., Ciui, B., Tertis, M., Sandulescu, R., & Cristea, C. (2019). Saliva, a magic biofluid available for multilevel assessment and a mirror of general health—A systematic review. Biosensors, 9(2), 27. https://doi.org/10.3390/bios9010027

Ilea, A., Andrei, V., Feurdean, C. N., Bab?an, A.-M., Petrescu, N. B., Câmpian, R. S., Bo?ca, A. B., Ciui, B., Ter?i?, M., Sandulescu, R., & Cristea, C. (2019). Saliva, a magic biofluid available for multilevel assessment and a mirror of general healt h-A systematic review. Biosensors, 9(1), 27.https://doi.org/10.3390/bios9010027

Jo, H., Gu, H., Jeon, W., Youn, H., Her, J., Kim, S. K., Lee, J., Shin, J. H., & Ban, C. (2015). Electrochemical aptasensor of cardiac troponin I for the early diagnosis of acute myocardial infarction. Analytical Chemistry, 87(19), 9869–9875. https://doi.org/10.1021/acs.analchem.5b02312

Jo, H., Gu, H., Jeon, W., Youn, H., Her, J., Kim, S.-K., Lee, J., Shin, J. H., & Ban, C. (2015). Electrochemical aptasensor of cardiac troponin I for the early diagnosis of acute myocardial infarction. Analytical Chemistry, 87(19), 9869–9875. https://doi.org/10.1021/acs.analchem.5b02312

Karachaliou, C.-E., & Livaniou, E. (2023). Immunosensors for autoimmune-disease-related biomarkers: A literature review. Sensors, 23(15), 6770. https://doi.org/10.3390/s23156770

Karimzadeh, Z., Hasanzadeh, M., Isildak, I., & Khalilzadeh, B. (2020). Multiplex bioassaying of cancer proteins and biomacromolecules: Nanotechnological, structural and technical perspectives. International Journal of Biological Macromolecules, 165(Part B), 3020–3039. https://doi.org/10.1016/j.ijbiomac.2020.10.191

Kaushal, A., Kaur, N., Sharma, S., Sharma, A. K., Kala, D., Prakash, H., & Gupta, S. (2022). Current update on biomarkers for detection of cancer: Comprehensive analysis. Vaccines, 10(12), 2138. https://doi.org/10.3390/vaccines10122138

Kim, J., Noh, S., Park, J. A., Park, S.-C., Park, S. J., Lee, J.-H., Ahn, J.-H., & Lee, T. (2021). Recent advances in aptasensor for cytokine detection: A review. Sensors, 21(24), 8491. https://doi.org/10.3390/s21248491

Lobo-Castañón, M. J., & Díaz-Fernández, A. (2025). Aptamer-based strategies for colorectal cancer detection: Emerging technologies and future directions. Biosensors, 15(11), 726. https://doi.org/10.3390/bios15110726

Lobo-Castañón, M. J., & Díaz-Fernández, A. (2025). Aptamer-based strategies for colorectal cancer detection: Emerging technologies and future directions. Biosensors, 15(11), 726.
https://doi.org/10.3390/bios15110726

Lopa, N. S., Rahman, M. M., Ahmed, F., Ryu, T., Sutradhar, S. C., Lei, J., Kim, J., Kim, D. H., Lee, Y. H., & Kim, W. (2019). Simple, low-cost, sensitive and label-free aptasensor for the detection of cardiac troponin I based on a gold nanoparticles modified titanium foil. Biosensors and Bioelectronics, 126, 381–388. https://doi.org/10.1016/j.bios.2018.11.012

Lopa, N. S., Rahman, M. M., Ahmed, F., Ryu, T., Sutradhar, S. C., Lei, J., Kim, J., Kim, D. H., Lee, Y. H., & Kim, W. (2019). Simple, low-cost, sensitive and label-free aptasensor for the detection of cardiac troponin I based on a gold nanoparticles modified titanium foil. Biosensors and Bioelectronics, 126, 381–388.
https://doi.org/10.1016/j.bios.2018.11.012

Mageswaran, N., Zainal, S. H., Hassan, N. I., Abd Karim, N. H., & Ismail, N. A. S. (2025). Emerging biomarkers and electrochemical biosensors for early detection of premature coronary artery disease. Diagnostics, 15(7), 940. https://doi.org/10.3390/diagnostics15070940

Majdinasab, M., & Marty, J. L. (2022). Recent advances in electrochemical aptasensors for detection of biomarkers. Pharmaceuticals, 15(8), 995. https://doi.org/10.3390/ph15080995

Malecka, K., Mikula, E., & Ferapontova, E. E. (2021). Design strategies for electrochemical aptasensors for cancer diagnostic devices. Sensors, 21(3), 736. https://doi.org/10.3390/s21030736

Mauriz, E. (2025). Trends and challenges of SPR aptasensors in viral diagnostics: A systematic review and meta-analysis. Biosensors, 15(4), 245. https://doi.org/10.3390/bios15040245

Mauriz, E. (2025). Trends and challenges of SPR aptasensors in viral diagnostics: A systematic review and meta-analysis. Biosensors, 15(4), 245. https://doi.org/10.3390/bios15040245

Mayoral-Peña, K., González Peña, O. I., Orrantia Clark, A. M., Flores-Vallejo, R. d. C., Oza, G., Sharma, A., & De Donato, M. (2022). Biorecognition engineering technologies for cancer diagnosis: A systematic literature review of non-conventional and plausible sensor development methods. Cancers, 14(8), 1867. https://doi.org/10.3390/cancers14081867

Moreira, M. J., Pintado, M., & De Almeida, J. M. M. M. (2024). Are aptamer-based biosensors the future of the detection of the human gut microbiome? A systematic review and meta-analysis. Biosensors, 14(5), 423. https://doi.org/10.3390/bios14090423

Nchouwat Ndumgouo, I. M., Chowdhury, M. Z. U., Andreescu, S., & Schuckers, S. (2025). Integrating AI with biosensors and voltammetry for neurotransmitter detection and quantification: A systematic review. Biosensors, 15(11), 729. https://doi.org/10.3390/bios15110729

Nchouwat Ndumgouo, I. M., Chowdhury, M. Z. U., Andreescu, S., & Schuckers, S. (2025). Integrating AI with biosensors and voltammetry for neurotransmitter detection and quantification: A systematic review. Biosensors, 15(11), 729. https://doi.org/10.3390/bios15110729

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71

Pultar, J., Sauer, U., Domnanich, P., & Preininger, C. (2009). Aptamer-antibody on-chip sandwich immunoassay for detection of CRP in spiked serum. Biosensors and Bioelectronics, 24(6), 1456–1461. https://doi.org/10.1016/j.bios.2008.08.052

Pultar, J., Sauer, U., Domnanich, P., & Preininger, C. (2009). Aptamer-antibody on-chip sandwich immunoassay for detection of CRP in spiked serum. Biosensors and Bioelectronics, 24(5), 1456–1461.
https://doi.org/10.1016/j.bios.2008.08.052

Radi, A.-E., & Abd-Ellatief, M. R. (2021). Electrochemical aptasensors: Current status and future perspectives. Diagnostics, 11(1), 104. https://doi.org/10.3390/diagnostics11010104

Radi, A.-E., & Abd-Ellatief, M. R. (2021). Electrochemical aptasensors: Current status and future perspectives. Diagnostics, 11(1), 104. https://doi.org/10.3390/diagnostics11010104

Redon, P., Shahzad, A., Iqbal, T., & Wijns, W. (2021). Development of a new detection algorithm to identify acute coronary syndrome using electrochemical biosensors for real-world long-term monitoring. Bioengineering, 8(3), 28. https://doi.org/10.3390/bioengineering8020028

Selvam, A. P., Wangzhou, A., Jacobs, M., Wu, T., Mohan, C., & Prasad, S. (2017). Development and validation of an impedance biosensor for point-of-care detection of vascular cell adhesion molecule-1 toward lupus diagnostics. Future Science OA, 3(4), FSO224. https://doi.org/10.4155/fsoa-2017-0047

Sequeira-Antunes, B., & Ferreira, H. A. (2023). Nucleic acid aptamer-based biosensors: A review. Biomedicines, 11(12), 3201. https://doi.org/10.3390/biomedicines11123201

Sequeira-Antunes, B., & Ferreira, H. A. (2023). Nucleic acid aptamer-based biosensors: A review. Biomedicines, 11(12), 3201. https://doi.org/10.3390/biomedicines11123201

Sheraz, M., Sun, X.-F., Wang, Y., Chen, J., & Sun, L. (2024). Recent developments in aptamer-based sensors for diagnostics. Sensors, 24(23), 7432. https://doi.org/10.3390/s24237432

Tan, L. L., & Mohamad, N. S. (2025). Electrochemical aptamer-based biosensors for sepsis diagnosis: Recent advances, challenges, and future perspectives (2020–2025). Biosensors, 15(7), 402. https://doi.org/10.3390/bios15070402

Tertis, M., Leva, P. I., Bogdan, D., Suciu, M., Graur, F., & Cristea, C. (2019). Impedimetric aptasensor for the label-free and selective detection of interleukin-6 for colorectal cancer screening. Biosensors and Bioelectronics, 137, 123–132. https://doi.org/10.1016/j.bios.2019.05.012

Tuerk, C., & Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249(4968), 505–510. https://doi.org/10.1126/science.2200121

Umapathy, V. R., Natarajan, P. M., Swamikannu, B., Moses, J., Jones, S., Chandran, M. P., & Anbumozhi, M. K. (2022). Emerging biosensors for oral cancer detection and diagnosis—A review unravelling their role in past and present advancements in the field of early diagnosis. Biosensors, 12(8), 498. https://doi.org/10.3390/bios12070498

Wang, F., Liu, Y., Fu, C., Li, N., Du, M., Zhang, L., Ge, S., & Yu, J. (2021). Paper-based bipolar electrode electrochemiluminescence platform for detection of multiple miRNAs. Analytical Chemistry, 93(4), 1702–1708. https://doi.org/10.1021/acs.analchem.0c04307

Wang, J., Guo, J., Zhang, J., Zhang, W., & Zhang, Y. (2017). RNA aptamer-based electrochemical aptasensor for C-reactive protein detection using functionalized silica microspheres as immunoprobes. Biosensors and Bioelectronics, 95, 100–105. https://doi.org/10.1016/j.bios.2017.04.014

Yan, M., Fu, L. L., Feng, H. C., & Namadchian, M. (2023). Application of Ag nanoparticles decorated on graphene nanosheets for electrochemical sensing of CEA as an important cancer biomarker. Environmental Research, 239, 117363. https://doi.org/10.1016/j.envres.2023.117363

Zambry, N. S., Ahmad Najib, M., Awang, M. S., Selvam, K., Khalid, M. F., Bustami, Y., Hamzah, H. H., Ozsoz, M., Abd Manaf, A., & Aziah, I. (2022). Aptamer-based electrochemical biosensors for the detection of Salmonella: A scoping review. Diagnostics, 12(12), 3186. https://doi.org/10.3390/diagnostics12123186


Article metrics
View details
0
Downloads
0
Citations
29
Views

View Dimensions


View Plumx


View Altmetric



0
Save
0
Citation
29
View
0
Share